Skip to content

MBX Biosciences, Inc. MBX Non Cash Operating Lease Expense

Non Cash Operating Lease Expense at other companies

Clearwater Analytics logo
Clearwater AnalyticsCWAN
$4.12M+73.6%
ServiceTitan, Inc. logo
ServiceTitan, Inc.TTAN
$1.51M+11.8%
BILL Holdings logo
BILL HoldingsBILL
$2.08M+0.7%
LifeStance Health Group logo
LifeStance Health GroupLFST
$10.72M+4.8%
Astrana Health logo
Astrana HealthASTH
$2.01M+55.8%
NTS
Netskope, Inc. Class A Common StockNTSK
$3.61M+14.6%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
Operating cash flow-$20.2M+10.9%
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept mbx:NonCashOperatingLeaseExpense.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s non cash operating lease expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s non cash operating lease expense?
MBX Biosciences, Inc. (MBX) reported non cash operating lease expense of $34K in Q1 2026.
How has MBX Biosciences, Inc.'s non cash operating lease expense changed year-over-year?
MBX Biosciences, Inc.'s non cash operating lease expense increased by 17.2% year-over-year, from $29K to $34K.
What does non cash operating lease expense mean?
This represents the portion of operating lease expenses that does not involve an immediate cash outflow, typically recognized under accounting standards like ASC 842. It reflects the systematic allocation of the right-of-use asset cost over the lease term. Investors use this to adjust net income to better reflect actual cash-based operating performance.